Guggenheim Securities Initiates Paratek Pharmaceuticals At Buy

Analysts at Guggenheim Securities initiated coverage on

with a Buy rating. The target price for Paratek Pharmaceuticals is set to $37. Paratek Pharmaceuticals shares have dropped 24.72 percent over the past 52 weeks, while the S&P 500 index has surged 11.57 percent in the same period. Paratek Pharmaceuticals' shares fell 3.21 percent to close at $26.56 on Friday.